# Randomised Controlled Trial Evidence on Medicinal Cannabis for Treatment of Mental Health and Substance Use Disorders: A Scoping Review. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/randomised-controlled-trial-evidence-medicinal-cannabis/ > **Published:** 2026-03-26T02:15:21-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:38:47-04:00 > **Clinical Summary:** Explore randomised controlled trial evidence medicinal cannabis for mental health and substance use disorders in this comprehensive scoping review. --- CED Clinical Relevance  #96High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. 🔬 Evidence Watch  |  CED Clinic Mental HealthPsychiatryRctEvidence-Based MedicineScoping Review Journal Clinical drug investigation Study Type Randomized Trial Population Human participants Why This Matters Mental health conditions represent some of the most common reasons patients seek [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/), yet the evidence base has been fragmented and inconclusive. This scoping review synthesizes the highest-quality randomized controlled trial data specifically for DSM-5 classified [mental health disorders](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/), providing clinicians with a clearer picture of where the evidence actually stands. Clinical Summary This scoping review systematically mapped all available RCT evidence for medicinal cannabis in treating mental health and substance use disorders as defined by DSM-5 criteria. The authors addressed previous limitations of heterogeneous study designs and quality that led to inconclusive findings in earlier reviews. While the summary doesn’t detail specific outcomes, this represents the most comprehensive synthesis of gold-standard trial evidence for cannabis in psychiatry to date. The review acknowledges the controversial and under-explored nature of cannabis for mental health applications, despite increasing global prescribing trends. Dr. Caplan’s Take “I’ve been waiting for exactly this kind of rigorous evidence synthesis. In my practice, mental health applications dominate patient inquiries, but until now we’ve been operating with scattered, often conflicting data that made evidence-based recommendations challenging.” Clinical Perspective 🧠 Clinicians should use this review as a definitive reference point for discussing [cannabis therapy](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) with patients presenting mental health conditions. The scoping methodology provides the comprehensive evidence map needed to identify which conditions have robust support versus those where evidence remains insufficient. This should inform both clinical decision-making and patient counseling about realistic expectations. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Randomised%20Controlled%20Trial%20Evidence%20on%20Medicinal%20Cannabis%20for%20Treatment%20of%20Ment...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41343139/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41343139/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Randomised%20Controlled%20Trial%20Evidence%20on%20Medicinal%20Cannabis%20for%20Treatment%20of%20Ment...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41343139/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41343139/](https://pubmed.ncbi.nlm.nih.gov/41343139/) Table of Contents - [FAQ](#FAQ)[Is there sufficient evidence to recommend medicinal cannabis for mental health conditions?](#Is_there_sufficient_evidence_to_recommend_medicinal_cannabis_for_mental_health_conditions) - [How does the evidence for mental health conditions compare to other medical uses of cannabis?](#How_does_the_evidence_for_mental_health_conditions_compare_to_other_medical_uses_of_cannabis) - [What are the main limitations in current research on medicinal cannabis for psychiatric conditions?](#What_are_the_main_limitations_in_current_research_on_medicinal_cannabis_for_psychiatric_conditions) - [Should clinicians consider prescribing medicinal cannabis for patients with mental health disorders?](#Should_clinicians_consider_prescribing_medicinal_cannabis_for_patients_with_mental_health_disorders) - [What safety considerations are important when evaluating medicinal cannabis for mental health treatment?](#What_safety_considerations_are_important_when_evaluating_medicinal_cannabis_for_mental_health_treatment) - [Related](#Related) ## FAQ #### Is there sufficient evidence to recommend medicinal cannabis for mental health conditions? Current evidence remains inconclusive for most mental health conditions. This scoping review found that while some evidence exists for specific conditions, the heterogeneity in study design and quality prevents definitive recommendations for DSM-5 classified [mental health disorders](https://cedclinic.com/cannabinoid-receptor-type-2-schizophrenia/). #### How does the evidence for mental health conditions compare to other medical uses of cannabis? The evidence base for mental health applications is less robust compared to conditions like multiple sclerosis and epilepsy, where emerging evidence shows more promise. Mental health applications remain controversial and under-explored in high-quality randomized controlled trials. #### What are the main limitations in current research on medicinal cannabis for psychiatric conditions? The primary limitations include significant heterogeneity in study designs, varying quality of trials, and inconsistent outcome measures across studies. These factors make it difficult to draw definitive conclusions about efficacy and safety profiles. #### Should clinicians consider prescribing medicinal cannabis for patients with mental health disorders? Given the inconclusive evidence and safety concerns, clinicians should exercise caution when considering medicinal cannabis for mental health conditions. Any decision should involve careful risk-benefit analysis and consideration of established evidence-based treatments first. #### What safety considerations are important when evaluating medicinal cannabis for mental health treatment? The safety and tolerability profile for mental health applications remains unclear based on current RCT evidence. Clinicians must consider potential psychiatric side effects, drug interactions, and the possibility of exacerbating certain mental health conditions before recommending use. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Randomised Controlled Trial Evidence on Medicinal Cannabis for Treatment of Mental Health and Substance Use Disorders: A Scoping Review.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41343139/”, “about”: “clinical drug investigation randomized trial randomised”, “isPartOf”: “Clinical drug investigation”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Endocannabinoid System Research: Cannabis Mental Health Care](https://cedclinic.com/clinical-trial-cannabis-mental-health-research/) Explore how the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) influences mental health and the therapeutic potential of [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/). [Learn More](https://cedclinic.com/clinical-trial-cannabis-mental-health-research/) [Cannabinoid Clinical Trials for Mental Disorders](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-efficacy/) Review key clinical trials investigating cannabinoids in the treatment of various mental health disorders. [Read Details](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-efficacy/) [Cannabinoids in Mental Health Treatment: A Systematic Review and Meta-Analysis](https://cedclinic.com/cannabinoids-mental-health-substance-use-disorders-review/) A comprehensive analysis of cannabinoids' effectiveness and safety in mental health treatment based on systematic review data. [Explore Findings](https://cedclinic.com/cannabinoids-mental-health-substance-use-disorders-review/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).